Trial reportEuropean journal of orthopaedic surgery & traumatology : orthopedie traumatologie2025
Intrathecal nalbuphine at two doses reduces opioid use and pain after total knee arthroplasty: a randomized controlled trial.
Trial report in European journal of orthopaedic surgery & traumatology : orthopedie traumatologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to assess the efficacy of different-dose intrathecal nalbuphine (ITN) in addition to adductor canal block (ACB) and its associated side effects.
methodsThis prospective randomized double-blinded controlled trial recruited 42 patients undergoing TKA at Naresuan University Hospital who received spinal anesthesia and ACB into three groups, each with 14 patients: Group A (control), Group B (additional ITN 0.8 mg), and Group C (additional ITN 1.2 mg). The primary outcome was the numeric rating scale (NRS) at rest and during movement at various time points. The secondary outcomes included the cumulative morphine use (CMU) and side effects.
resultsForty-two patients (group A = 14; group B = 14; group C = 14) were randomized. All patients were analyzed. The group C had significantly lower NRS at rest at 6, 12, 24, and 48 h postoperatively, and significantly lower NRS during movement at 6 and 36 h postoperatively when compared to group A. There was no significant difference in NRS between group C and B, or between group B and A. The group B and C required significantly less CMU than the group A during the first 24, 48, and 72 h after TKA. The side effects, which included nausea, vomiting, drowsiness, respiratory depression, and shivering, were not significantly different among the groups.
conclusionAdditional ITN, both 0.8 and 1.2 mg doses, effectively reduces CMU during the first 72 h after TKA. Given higher-dose ITN up to 1.2 mg provides benefit by further reducing pain scores, without increased side effects. TRIAL REGISTRATION CLINICAL TRIALS: TCTR20241012005, October 12, 2024.
Indexed as
Identifiers
40779077What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.